Literature DB >> 23295727

Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas.

Maurits de Vries1, Inge Briaire-de Bruijn, Martijn J A Malessy, Sica F T de Bruïne, Andel G L van der Mey, Pancras C W Hogendoorn.   

Abstract

HYPOTHESIS: Tumor-associated macrophages contribute to vestibular schwannoma development.
OBJECTIVE: An important clinical problem regarding vestibular schwannoma treatment is their variable growth rate. Tumor biological research can help to clarify this growth rate and may offer targets for therapy. Inflammation is an important biological process involved in the development of many solid tumors. Macrophages are major determinants of intratumoral inflammation. Macrophages can be divided into two groups; the M1- and M2-type macrophages. M2-type macrophages are associated with tumor-promoting processes like angiogenesis, tumor cell growth, and downregulation of the antitumor immune response. Both macrophages and angiogenesis can serve as targets for therapy. CD163 is a specific marker for M2-type macrophages. The goal of this study was to investigate if the expression of CD163 positive macrophages in sporadic vestibular schwannomas is associated with angiogenesis and tumor growth.
METHODS: CD163 expression in 10 fast-growing vestibular schwannomas was compared with CD163 expression in 10 slow-growing vestibular schwannomas. Tumor growth was determined by comparing preoperative tumor volume measurements on MRI. The relation between macrophage expression and angiogenesis was evaluated by assessing microvessel density (CD31).
RESULTS: CD163 expression and microvessel density were significantly higher in fast-growing vestibular schwannomas (p < 0.001 and p = 0.019, respectively). Tumors with higher CD163 expression contained significantly more microvessels (p = 0.014).
CONCLUSION: This study demonstrates that M2-type macrophages in vestibular schwannomas relate to angiogenesis and volumetric tumor growth. These results imply that the M2-type macrophage infiltrate contributes to progressive tumor growth, making it a potential target for pharmacologic therapy. (C) 2013 Otology & Neurotology, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295727     DOI: 10.1097/MAO.0b013e31827c9fbf

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  19 in total

1.  Macrophage Density Predicts Facial Nerve Outcome and Tumor Growth after Subtotal Resection of Vestibular Schwannoma.

Authors:  Christopher S Graffeo; Avital Perry; Aditya Raghunathan; Trynda N Kroneman; Mark Jentoft; Colin L Driscoll; Brian A Neff; Matthew L Carlson; Jeffrey Jacob; Michael J Link; Jamie J Van Gompel
Journal:  J Neurol Surg B Skull Base       Date:  2018-02-07

2.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

Review 3.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macrophages, and possible therapeutic implications: a comprehensive review.

Authors:  Yosef Laviv; Burkhard Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-11       Impact factor: 3.042

4.  Response prediction of vestibular schwannoma after gamma-knife radiosurgery using pretreatment dynamic contrast-enhanced MRI: a prospective study.

Authors:  Inpyeong Hwang; Seung Hong Choi; Jin Wook Kim; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn
Journal:  Eur Radiol       Date:  2022-01-27       Impact factor: 5.315

Review 5.  Adrenal schwannoma: why should endocrinologists be aware of this uncommon tumour?

Authors:  Giuseppina Incampo; Luigi Di Filippo; Erika Maria Grossrubatscher; Paolo Dalino Ciaramella; Stefano Frara; Andrea Giustina; Paola Loli
Journal:  Endocrine       Date:  2022-02-12       Impact factor: 3.633

Review 6.  Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.

Authors:  Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

Review 7.  Evaluating growth trends of residual sporadic vestibular schwannomas: a systematic review and meta-analysis.

Authors:  Abdullah Egiz; Hritik Nautiyal; Andrew F Alalade; Nihal Gurusinghe; Gareth Roberts
Journal:  J Neurooncol       Date:  2022-06-27       Impact factor: 4.506

8.  Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth.

Authors:  Sherif G Ahmed; Giulia Oliva; Manlin Shao; Xinhui Wang; John J Mekalanos; Gary J Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-08       Impact factor: 12.779

9.  Dramatic Growth of a Vestibular Schwannoma After 16 Years of Postradiosurgery Stability in Association With Exposure to Tyrosine Kinase Inhibitors.

Authors:  Lucas P Carlstrom; Amanda Muñoz-Casabella; Avital Perry; Christopher S Graffeo; Michael J Link
Journal:  Otol Neurotol       Date:  2021-12-01       Impact factor: 2.619

10.  Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Authors:  Ryota Tamura; Yukina Morimoto; Mizuto Sato; Yuki Kuranari; Yumiko Oishi; Kenzo Kosugi; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.